Short Oligonucleotide Technique (SOT)

Supportive Oligonucleotide Technique (SOT) has shown to be a very effective cancer support technique from clinical experience over the last 9 months, 85 patients and 151 doses given as of (7.25.13). This same methodology has been used in Europe for many years now.


A similar technique called antisense has been known and used for at least 15 years. However, there are distinctive differences between antisense (as traditionally used) and SOT.


SOT is not a genetic therapy, as is most antisense treatments and no genotoxic (chemo) drugs are used. RGCC-Labs uses mRNA's to only influence certain gene expressions not to change genetic structure. RGCC-labs uses mRNA expression fingerprinting in order to identify certain gene expression patterns as targets but without influence to the genetic structure (epigenetic). Based on this analysis RGCC-Labs uses the mRNA analysis of each individuals CTC's/CSC's and occasionally from biopsies of the tumor, and generates the SOT. As of today, following extensive searches, we know of no one or other entity making this type of technique this way anywhere in the world (as of 7.21.13).


SOT has the ability to induce apoptosis (cell death) in the CTC's, CSC's (circulating cancer tumor & stem cells) and ALL primary and metastatic tumors (regardless of size, and is able to cross the blood brain barrier with ease). SOT will remain active in the blood stream for approximately 14-16 weeks (maybe longer) per dose. Because, the mRNA actually features a stealth like ability that keeps the body from recognizing and destroying it. SOT will work 24/7 and has no decreased efficacy with any concurrent technique except chemotherapy and/or radiation.


 How does SOT work? 

 

RGCC Laboratory located in Greece is a genetic laboratory which is capable of identifying the specific gene sequences of different targets such as cancer, lyme and other viruses. We send a patient's blood to their lab and they identify the main genetic sequence (gene epitope) of our target genes. Once they identify the main genetic epitope of the target, they cross reference the gene sequences to an international database of genetics to ensure they have the proper sequences. 


RGCC created this unique fingerprinting technology so that we can ensure the success of this treatment. It creates a 98% specificity to our target genes such as the Lyme Spirochetes and it does not interfere with any other human cells. Once the replication genes (sense strand) are identified, the laboratory creates the anti-copy of the replication sequences of the translocation genes. The sense strand is the particular code of the genetics that creates replication in the cell. RGCC splices apart the sense strand and makes a complimentary copy of the DNA sequences that creates replication. This in turn creates an anti-sense therapy.  

 

Once they create the complimentary copy of the replication sequences, they surround this copy with a synthetic messenger RNA so that it has the ability to penetrate within the cell wall of our target. Once this mRNA sequence is created, they replicate this to 500 million to 1 billion copies of your unique SOT molecules. These molecules are delivered to our office where you receive your one dose IV treatment.  


Once you receive your SOT molecules, they are at work 24-hours a day,  seven days a week for up to six months inhibiting the replication cycle of your target spirochetes. 

The Lyme spirochetes have a life cycle of 80 days. It is the longest life-cycle of any bacteria in science and it has one of the most complicated gene sequences that we study. One point of interest is to note that this treatment is not an immune treatment and it does not work through the immune activation system therefore there is very minimal side effects. SOT works simply by shutting down the gene replication sequences of our target therefore eliminating the next life-cycle.  Once the life-cycle of the spirochete has been completed there are just simply no spirochetes left.  


In summary, when the genetic sequence of a particular gene is known to be a causative agent of a particular disease, it is possible to synthesize a strand of nucleic acid (DNA, RNA or a chemical analogue) that will bind to the messenger RNA (MRNA) produced by that gene and effectively turning that gene “off”. This is called gene silencing therapy or apoptosis inducing therapy. 


image4

AOT/SOT for Lyme,Co-infection, Viruses

 

AOT is a treatment that was originally created in Europe over 20 years ago by the name of antisense oligonucleotide therapy (AOT). 


If you are searching online for this treatment, it is best to look for it under the name of Antisense Oligonucleotide Therapy. There are lots of research from European and American based companies and universities. 


RGCC labs in Greece has improved this technology over the previous technology and renamed it as an SOT because they create a treatment based on the patient’s unique genotype that is tested from their blood. We know of no other laboratory in the world that is creating this unique process. In the United States, we now cure hepatitis C with this exact same FDA approved technology. So, if we can turn off hepatitis C with one dose of an anti-sense therapy then we can definitely turn off the other replication cycles of Lyme disease, Lyme co-infections, viruses and even cancer cells.



Over the past two decades, Anti-Sense Oligonucleotide Technology has emerged as a valid approach to selectively modulate gene expressions in various targets. The recent acceleration of science and the ability to identify new molecular targets for cancer, Lyme and other viruses, has driven new advances in this technology. The limited effectiveness of conventional treatment strategies has focused considerable interest on the technology and development of new types of gene silencing therapies.


 

How does SOT work?

RGCC Laboratory located in Greece is a genetic laboratory which is capable of identifying the specific gene sequences of different targets such as cancer, Lyme and other viruses. We send a patient's blood to their lab and they identify the main genetic sequence (gene epitope) of our target genes. Once they identify the main genetic epitope of the target, they cross reference the gene sequences to an international database of genetics to ensure they have the proper sequences. RGCC created this unique fingerprinting technology so that we can ensure the success of this treatment. It creates a 98% specificity to our target genes such as the Lyme Spirochetes and it does not interfere with any other human cells. Once the replication genes (sense strand) are identified, the laboratory creates the anti-copy of the replication sequences of the translocation genes. The sense strand is the particular code of the genetics that creates replication in the cell. RGCC splices apart the sense strand and makes a complimentary copy of the DNA sequences that creates replication. This in turn creates an anti-sense therapy.  

 

Once they create the complimentary copy of the replication sequences, they surround this copy with a synthetic messenger RNA so that it has the ability to penetrate within the cell wall of our target. Once this mRNA sequence is created, they replicate this to 500 million to 1 billion copies of your unique SOT molecules. These molecules are delivered to our office where you receive your one dose IV treatment.  

Once you receive your SOT molecules, they are at work 24-hours a day,  seven days a week for up to six months inhibiting the replication cycle of your target spirochetes. 

The Lyme spirochetes have a life cycle of 80 days. It is the longest life cycle of any bacteria in science and it has one of the most complicated gene sequences that we study. One point of interest is to note that this treatment is not an immune treatment and it does not work through the immune activation system therefore there is very minimal side effects. SOT works simply by shutting down the gene replication sequences of our target therefore eliminating the next life cycle.  Once the life cycle of the spirochete has been completed there are just simply no spirochetes left.  

In summary, when the genetic sequence of a particular gene is known to be a causative agent of a particular disease, it is possible to synthesize a strand of nucleic acid (DNA, RNA or a chemical analogue) that will bind to the messenger RNA (MRNA) produced by that gene and effectively turning that gene “off”. This is called gene silencing therapy or apoptosis inducing therapy. 


image5

Antisense

Module 1 Animation - How Antisense Drugs Work